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Abstract
Tumor behavior is affected by the tumor microenvironment, composed of cancer-associated fibroblasts (CAFs). Meanwhile,
hepatocellular carcinomas (HCC) with fibrous stroma reportedly exhibit aggressive behavior suggestive of tumor-stroma
interaction. However, evidence of the crosstalk remains unclear. In this study, CCN2, epithelial membrane antigen (EMA),
fibroblast activation protein (FAP), and keratin 19 (K19) expression was studied in 314 HCCs (cohort 1), 42 scirrhous HCCs
(cohort 2), and 36 chronic hepatitis/cirrhosis specimens by immunohistochemistry. Clinicopathological parameters were
analyzed according to the expressions of these markers. In tumor epithelial cells from cohort 1, CCN2 and EMA were
expressed in 15.3% and 17.2%, respectively, and their expressions were more frequent in HCCs with fibrous stroma ($5% of
tumor area) than those without (P,0.05 for all); CCN2 expression was well correlated with K19 and EMA expression. In
tumor stromal cells, FAP expression was found in 6.7%. In cohort 2, CCN2, EMA, and FAP expression was noted in 40.5%,
40.5%, and 66.7%, respectively, which was more frequent than that in cohort 1 (P,0.05 for all). Additionally, EMA expression
was associated with the expression of K19, CCN2, and FAP (P,0.05 for all); EMA expressing tumor epithelial cells showed a
topographic closeness to FAP-expressing CAFs. Analysis of disease-free survival revealed CCN2 expression to be a worse
prognostic factor in both cohort 1 (P= 0.005) and cohort 2 (P= 0.023), as well as EMA as a worse prognostic factor in cohort
2 (P= 0.048). In conclusion, expression of CCN2, EMA, and FAP may be involved in the activation of CAFs in HCC, giving rise
to aggressive behavior. Significant correlation between EMA-expressing tumor cells and FAP-expressing CAFs and their
topographic closeness suggests possible cross-talk between tumor epithelial cells and stromal cells in the tumor
microenvironment of HCC.
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Introduction
The biological behavior of tumors is reportedly affected by not
only malignant tumor cells themselves but also by the tumor
microenvironment including tumor stroma [1–3]. The tumor
stroma is a complicated system that consists of signaling molecules,
extracellular matrix proteins, proteolytic enzymes, blood vessels,
and a variety of cellular components, such as cancer-associated
fibroblasts (CAFs) and immune cells [4,5]. CAFs in tumor stroma
are histologically categorized as myofibroblasts or activated
fibroblasts, and they have been reported to be associated with
aggressive biological behavior, poor prognosis, and resistance to
chemotherapy and radiation therapy in breast cancer, pancreatic
cancer, and colon cancer [6–10]. Therefore, CAFs could influence
the biological characteristics of tumor cells through tumor-stroma
cross-talk. However, crosstalk between tumor cells and activated
fibroblasts has not been fully explored in HCCs.
Hepatocellular carcinoma (HCC) is the seventh most common
malignancy worldwide and the third greatest cause of cancer
related mortality, especially in Asia and sub-Saharan Africa [11].
Most HCCs contain no or only little amounts of fibrous stroma;
nevertheless, some HCCs without history of preoperative treat-
ment exhibit various amounts of fibrous stroma between tumor
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nests. In a previous study, we showed that HCC specimens with
abundant fibrous stroma, known as scirrhous HCC, exhibit an
aggressive biological behavior and the expression of ‘‘stemness’’-
related markers, along with activation of TGF-b signature and
epithelial-mesenchymal transition (EMT)-related genes [12].
CCN2 (previously known as connective tissue growth factor,
IGFBP8, etc.), a fibrogenic cytokine, is involved in virtually all
fibrotic pathologies, both benign and malignant [13]. Recently,
CCN2 expression was reported to be impeded by TGF-b receptor
inhibition, resulting in a decrease of the stromal components in
HCC [14]. Epithelial membrane antigen (EMA) is a member of a
family of transmembrane mucin glycoproteins, with a high
carbohydrate content and extensive O-linked glycosylation of its
extracellular domain [15]. Recently, EMA mRNA was reported to
be up-regulated in a co-culture study of hepatoma cells and
activated hepatic stellate cells (HSCs), compared to stromal cells
cultured alone [16]. Furthermore, clinical studies have reported a
relationship between EMA expression and poor prognosis in
various malignant tumors, including lung cancer, gastric cancer,
gallbladder cancer, and HCC [17–20]. Fibroblast activation
protein (FAP), a member of the serine protease family, has been
reported to increase stromal cell proliferation and invasiveness, as
well as reduce cell apoptosis [21]. FAP is also recognized as a
useful marker of CAFs, selectively expressed in fibroblasts of
several epithelial cancers, and is reported to be related to worse
prognosis of pancreatic adenocarcinoma and colon cancer [21–
24].
Concerning the tumor microenvironment of HCCs, the
molecular mechanism involved in the formation of tumor fibrous
stroma and tumor-stroma cross-talk remains unclear. Thus, we
attempted to evaluate the expressions of CCN2, EMA, and FAP
and their correlation with clinicopathological features of HCCs. As
well, their topographic expression patterns were further examined
in HCCs with abundant fibrous stroma (scirrhous HCCs).
Materials and Methods
Patients and clinicopathological analysis
The HCC specimens included in this study were morpholog-
ically typical of HCC, and cases that could be classified as
combined hepatocellular-cholangiocarcinoma or with a history of
preoperative treatment were excluded. Formalin-fixed, paraffin-
embedded HCC specimens were obtained from the archives of the
Department of Pathology, Severance Hospital, Yonsei University
College of Medicine. Liver specimens were provided by the Liver
Cancer Specimen Bank, National Research Resource Bank
program of the Korea Science and Engineering Foundation of
the Ministry of Science and Technology. This study was approved
by the Institutional Review Board of Severance Hospital, Yonsei
University College of Medicine (Seoul, Korea). The Institutional
Review Board waived the need for consent (4-2013-0912).
This study was performed in specimens from two cohorts of
patients with HCC. Cohort 1 consisted of 314 cases of HCC from
January 2007 to March 2011; there were 254 males and 60
females, ranging in age from 28 to 81 years (55.6610.1, mean
6SD). To investigate the spatial relationship between epithelial
cells and CAFs, cohort 2 included 42 cases of HCC with abundant
fibrous stroma ($50% of the tumor area) (scirrhous HCC). The
specimens were obtained from September 2001 to December
2010, there were 29 males and 13 females, whose ages ranged
from 27 to 71 years (range, 53.768.3, mean 6SD). Twenty-five
cases were included in both of cohort 1 and 2. As a control group,
36 non-tumor tissues of chronic hepatitis/cirrhosis were studied.
Histopathologic analysis was performed for both cohorts on
whole sections of representative tissue blocks. For each case, tumor
size, differentiation according to Edmondson-Steiner grade, tumor
capsule formation, lymphovascular invasion, multiplicity of
tumors, presence of fibrous stroma, and pathology of non-
neoplastic liver were recorded. In cohort 1, presence of fibrous
stroma was defined as fibrotic areas $5% of the tumor area.
Figure 1. Connective tissue growth factor (CCN2), epithelial membrane antigen (EMA), fibroblast activation protein (FAP), and
keratin 19 (K19) expression in hepatocellular carcinomas (HCCs) of cohort 1. A) Small nests of tumor cells are surrounded by fibrous
stroma. B) Immunohistochemistry for CCN2 exhibits diffuse cytoplasmic expression in tumor epithelial cells of HCC. C–D) Immunohistochemistry for
EMA reveals patchy or focal expression pattern in tumor epithelial cells of HCC. E–F) K19 is focally positive in the periphery of tumor nests. (G–H) FAP
is expressed in the cytoplasm of cancer-associated fibroblasts of tumor stroma. (Scale bars represent 100 mm.)
doi:10.1371/journal.pone.0105094.g001
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Clinical data from each patient were obtained from a careful
review of their medical records, including hepatitis B virus surface
antigen status, hepatitis C virus antibody, and tumor-node-
metastasis (TNM) classification according to the 7th American
Joint Committee on Cancer/International Union against Cancer
(AJCC/UICC) staging system.
Tissue microarray construction
A representative formalin-fixed, paraffin-embedded block con-
taining HCC was selected for each of the 314 available cases of
cohort 1. The arrays were constructed in triplicate using a 3-mm
punch on a tissue-arraying instrument (Beecher Instruments,
Silver Springs, FL, USA). The cases were reviewed on conven-
tional hematoxylin and eosin-slides, and representative areas were
marked on each slide. Using a marker pen, the corresponding
region was circled on the ‘‘donor’’ paraffin block. The samples
were then arrayed on to a ‘‘recipient’’ block.
Immunohistochemistry
Immunohistochemical stain was performed using tissue micro-
arrays from cohort 1 and paraffin-embedded whole tissue sections
for topographic assessment from cohort 2. To compare the
phenotypical characteristics between CAFs of tumor fibrous
stroma and fibroblasts in benign fibrous stroma, 36 cases of
chronic hepatitis or cirrhosis, which included at least 10 portal
tracts, were also immunostained.
The primary antibodies used were anti- CCN2 (1:300, Abcam,
Cambridge, UK), anti-EMA (1:100, Dako, Glostrup, Denmark),
anti-FAP (D8, 1:100, Vitatex, Stony Brook, NY, USA), and
Keratin 19 (K19) (1:100, Dako). Immunohistochemical stain for
CCN2, EMA, and K19 was performed using automated staining
system (Discovery XT, Ventana Medical Systems, AZ, USA), and
that for FAP was performed using horseradish peroxidase-
conjugated ant-rat immunoglobulin and Envision kit (DAKO)
according to the manufacturer’s instructions. All immunohisto-
chemical markers were assessed by a light microscope. The
immunohistochemical staining results were interpreted in a
semiquantitative way and given a staining score, from 0 to 3, as
follows: 0, staining in ,5% of tumor cells; 1, weak staining in $
5%; 2, moderate staining in $5%; and 3, strong staining in $5%
of the tumor cells. Positive staining was defined as a staining score
of 2 or 3, whereas scores of 0 and 1 were regarded as negative.
Two pathologists (G. J. Kim and Y. N. Park) assessed the staining
results without awareness of the clinicopathological data for each
case.
Statistical analysis
Statistical analyses were performed using SPSS software version
20.0 for Windows (SPSS Inc., Chicago, IL, USA). Categorical
variables were analyzed by the chi-square test or Fisher’s exact
test. On survival analysis, clinicopathologic variables were
dichotomized and analyzed according to their effect on prognosis.
Disease-free survival (DFS) and overall survival (OS) analysis was
performed using the Kaplan–Meier method, and differences
between the groups were assessed using the log-rank test.
Univariate and multivariate survival analyses were carried out
using Cox proportional hazard regression models. Only variables
significant in the univariate analysis of factors affecting survival
were used in the stepwise multivariate analysis. Estimated relative
risks of death were expressed as adjusted hazard ratios (HR) and
corresponding 95% confidence intervals (CI). Statistical signifi-
cance was assumed for P-values ,0.05.T
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Results
CCN2, EMA, and FAP expression and the
clinicopathological characteristics of HCC (Cohort 1,
n = 314)
To assess the expressions of CCN2, EMA, K19, and FAP in
HCCs in regards to their clinicopathologic significance, we
investigated these markers by immunohistochemistry of tissue
microarrays from 314 cases of HCC (cohort 1). Positive expression
rates of CCN2, EMA, K19, and FAP were 15.3% (48/314),
17.2% (54/314), 22.3% (70/314), and 6.7% (21/314), respective-
ly. CCN2, EMA, and K19 expression was noted in tumor
epithelial cells, but not in CAFs. CCN2 was diffusely expressed
throughout the tumor cells upon cytoplasmic staining (Figure 1.
A–B). Expression of EMA, on the contrary, was either patchy or
diffuse in the tumor cells upon membranous and/or cytoplasmic
staining (Figure 1. C–D). K19 was focally expressed in the tumor
cells upon cytoplasmic and/or membranous staining (Figure 1. E–
F). FAP was, on the other hand, expressed in the cytoplasm of
CAFs, but not in tumor epithelial cells (Figure 1. G–H).
The expressions of CCN2, EMA, and FAP were evaluated
according to clinicopathologic parameters of HCC (Table 1).
CCN2 expression was significantly related to background cirrhosis
(P=0.035), absence of tumor capsule (P=0.049), and presence of
tumor fibrous stroma in HCC (P=0.028). EMA expression
demonstrated a significant association with presence of tumor
fibrous stroma only (P=0.003). Expression of CCN2 was
significantly correlated with K19 immunoreactivity (P=0.018),
whereas EMA expression was not. FAP expression was signifi-
cantly correlated with a solitary tumor mass (P=0.031), but it was
not significantly correlated with any other clinicopathologic
parameter (P.0.05).
Expression rates of CCN2 and EMA were significantly
correlated with each other (P=0.001). Among 48 cases that
exhibited CCN2 expression, 16 cases (33.3%, 16/48) were positive
for EMA. In the CCN2 negative cases, however, the expression
rate of EMA was relatively low (14.3%, 38/266). The expressions
of CCN2 and FAP showed no significant correlation with each
other (P=0.752); two cases (4.2%, 2/48) were positive for FAP in
the CCN2 positive group and 19 cases (7.1%, 19/266) were
positive for FAP in the CCN2 negative group. As well, the
expressions of EMA and FAP also showed no significant
correlation with each other (P=0.406); five cases (9.3%, 5/54)
were positive for FAP in the EMA positive group and 16 cases
(6.2%, 16/260) were positive for FAP in the EMA negative group.
CCN2, EMA, and FAP expression and the
clinicopathological characteristics of HCCs with
abundant fibrous stroma (scirrhous HCC) (Cohort 2,
n = 42)
The expressions of CCN2 and EMA were significantly
correlated with each other and also with the presence of tumor
fibrous stroma in cohort 1. These results might imply cross-talk
between CCN2 and EMA expression and tumor fibrous stromal
components. As most HCCs of cohort 1 showed no or little tumor
fibrous stroma, we evaluated the expressions of these markers in
another cohort of scirrhous HCC, which had abundant ($50% of
tumor area) fibrous stroma. Whole tumor sections from represen-
tative paraffin-embedded tissue blocks were used to assess the
topographic expression patterns of CCN2, EMA, K19, and FAP
in scirrhous HCCs. Therein, the positive expression rates of
CCN2, EMA, K19, and FAP were 40.5% (17/42), 40.5% (17/42),
33.3% (14/42), and 66.7% (28/42), respectively. The expression
rates of CCN2, EMA, K19, and FAP in cohort 2 were significantly
higher than those in cohort 1 (P,0.001, P= 0.001, P= 0.013, P,
0.001, respectively).
In comparison of tumor fibrous stroma of HCC and benign
fibrous stroma of the liver, the expressions of CCN2, EMA, and
FAP were investigated in specimens of chronic hepatitis/cirrhosis
(n = 36) (Figure 2). CCN2 and EMA were not detected in either
stromal cells or hepatocytes of chronic hepatitis/cirrhosis speci-
mens. Additionally, FAP was not expressed in the stromal cells of
most cases of chronic hepatitis/cirrhosis, and it was only focally
detected in stromal cells from three cases (3/36, 8.3%) of chronic
hepatitis/cirrhosis. Moreover, FAP was not noted in any benign
hepatocytes for all cases. Accordingly, FAP expression was
significantly higher in CAFs from HCCs than in benign fibrous
stroma from chronic hepatitis/cirrhosis specimens (P=0.012).
The EMA expression rate was significantly higher in HCCs
with CCN2 expression, compared to those without (P=0.046).
Ten cases (58.8%, 10/17) were positive for EMA among CCN2
positive specimens, while EMA was expressed in only seven
(28.0%, 7/25) CCN2 negative specimens. Moreover, the EMA
expression rate was also significantly higher in HCCs with FAP
expression, compared to those without (P=0.020), in this cohort.
Fifteen cases (53.6%, 15/28) were positive for EMA among FAP
positive specimens, while EMA was expressed in only two (14.3%,
2/14) FAP negative specimens. Additionally, EMA expression was
associated with K19 expression; K19 was positive in 52.9% (9/17)
of EMA positive cases and negative in 20.0% (5/25) of EMA
negative cases (P=0.026). The expressions of CCN2 and FAP
showed no significant correlation with each other (P=0.331); 13
cases (76.5%, 13/17) were positive for FAP among CCN2 positive
specimens and 15 cases (60.0%, 15/25) were positive for FAP
among CCN2 negative specimens.
CCN2 was diffusely expressed in tumor epithelial cells without a
specific pattern and the CCN2-expressing tumor cells were closely
surrounded by tumor stroma with FAP-expressing CAFs (Fig-
ure 3. A–C). EMA exhibited focal or diffuse expression in the
cytoplasm and/or membranes of tumor epithelial cells. The
Figure 2. Connective tissue growth factor (CCN2), epithelial
membrane antigen (EMA), fibroblast activation protein (FAP),
and keratin 19 (K19) expression in liver cirrhosis. A) Liver
cirrhosis showing regenerative hepatic nodules and fibrotic septa with
chronic inflammatory cells. CCN2 (B), EMA (C), and FAP (D) expression is
negative in both hepatocytes and benign stromal cells from cirrhosis
specimens. (Scale bars represent 100 mm.)
doi:10.1371/journal.pone.0105094.g002
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topographical expression pattern thereof was further assessed in 17
cases positive for EMA expression, including six cases of a large
tumor nest pattern and 11 cases of a small tumor nest/trabecular
pattern. Interestingly, EMA expression patterns demonstrated
topographic closeness between the tumor epithelial cells and CAFs
of tumor stroma: EMA expression was noted at the periphery of
tumor nests, where the tumor cells were more closely in contact
with the FAP-expressing tumor stroma in 50% (3/6) of cases with
a large tumor nest pattern (Figure 3. D–F). Meanwhile, all 11
cases of a small nest/trabecular pattern showed diffuse expression
of EMA, and tumor cells expressing EMA were surrounded by
FAP-expressing tumor stroma (Figure 3. G–I).
The clinicopathological features of HCC according to the
expressions of CCN2, EMA, and FAP in HCCs with fibrous
stroma are summarized in Table 2. CCN2 expression rate was
significantly higher in large tumors ($5 cm), compared to small
ones (,5 cm) (P=0.023). FAP expression rate was significantly
higher in HCCs with vascular invasion, compared to those without
(P=0.030).
Prognostic significance of CCN2, EMA, and FAP
expression
All HCC patients underwent curative resection, and the mean
follow-up times were 31.2 months (range, 0–76) in cohort 1 and
44.6 months (range, 8–138) in cohort 2.
Among the 314 HCC patients of cohort 1, DFS rate was
significantly lower in HCC patients expressing CCN2, compared
to those that did not (P=0.005, Figure 4A); EMA and FAP
expression was not associated with patient outcomes in this cohort
(P=0.362 and P=0.287, respectively) (Figure 4. B–C). Univari-
able analysis revealed background cirrhosis (P=0.002), large
tumor size ($5 cm) (P=0.001), high Edmondson grade
(P=0.007), vascular invasion (P,0.001), multiple tumors (P,
0.001), tumor stage III/IV (P,0.001), and CCN2 expression
(P=0.005) to be adverse prognostic factors for DFS after surgery.
Subsequent multivariable analysis indicated background cirrhosis
(HR=1.815, P=0.004) and vascular invasion (HR=1.764,
P=0.015) as independent prognostic factors for DFS after
surgery; CCN2 expression was not significant in multivariate
Figure 3. Connective tissue growth factor (CCN2), epithelial membrane antigen (EMA), and fibroblast activation protein (FAP)
expression in scirrhous hepatocellular carcinomas (HCCs with abundant fibrous stroma) of cohort 2. A–C) CCN2 (B) is diffusely
expressed in the nests of tumor epithelial cells, and the tumor stromal cells between the nests of tumor epithelial cells exhibit strong FAP expression
(C). D–F) EMA is mainly expressed in the periphery (E, arrows) of large tumor nests in contact with FAP-expressing cancer-associated fibroblasts (CAFs)
of tumor fibrous stroma (F, arrowheads). G–I) HCCs with small nests or a trabecular pattern show diffuse expression for EMA in the tumor epithelial
cells (H), which are closely admixed with FAP-expressing CAFs of tumor stroma. (Scale bars represent 100 mm.)
doi:10.1371/journal.pone.0105094.g003
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analysis (HR=1.561, P=0.056, Table 3). Additionally, OS rate
was not significant different according to expression of these
markers (P.0.05).
In cohort 2, consisting of 42 scirrhous HCCs, DFS rates were
significantly lower for both CCN2-positive and EMA-positive
specimens, compared to negative specimens (P=0.023 and
P=0.048, respectively, Figure 4. D–E). Nevertheless, there were
no differences in OS rates according to CCN2 and EMA
expression (P=0.484 and 0.230, respectively). As well, expression
of FAP showed no correlation with DFS (P=0.283, Figure 4F)
and OS (P=0.820), respectively.
Discussion
Tumor behavior is affected by not only malignant tumor cells
themselves but also by the tumor microenvironment, including
CAFs [2,4,5]. Although, HCCs usually show no or only little
amounts of fibrous stroma, in our previous study, we found that so
called scirrhous HCCs, HCCs with abundant fibrous stroma,
exhibit an aggressive biological behavior, along with expression of
stemness-related markers and activation of TGF-b signature and
EMT-related genes [12]. These findings suggest tumor-stroma
interaction in HCC; however, the activation mechanisms thereof
remain unclear.
FAP was initially identified as being expressed in reactive
fibroblasts for embryonic development or in chronic inflammation
[25,26]. More importantly, FAP is recognized as a marker of
CAFs, and is reported to increase stromal cell proliferation and
invasiveness, reduce cell apoptosis, and to be associated with worse
prognosis in colon cancer and pancreas cancer [21–24]. The
present study found that FAP is expressed predominantly in CAFs
from the tumor fibrous stroma of HCCs, and is significantly
correlated with frequent vascular invasion in scirrhous HCCs. In
contrast, FAP expression was rarely found in benign fibrotic tissue
of chronic hepatitis/cirrhosis. These findings suggest that FAP is
involved in the activation of CAFs in tumor stroma, which differ
from benign fibroblasts in the fibrous tissue of chronic hepatitis/
cirrhosis.
An in vitro co-culture model study of human hepatoma cells
and activated HSCs demonstrated increases in EMA mRNA when
those cells were cultured together, compared to culture of stromal
cells alone [16]. Our study revealed significantly higher rates of
EMA expression in HCCs with fibrous stroma ($5% of tumor
area), compared to those without (cohort 1), and this was related to
poor DFS in scirrhous HCC patients (cohort 2). These findings
were consistent with previous reports that EMA was a poor
prognostic factor in HCC [17,27]. Interestingly, in HCCs with
large tumor nests, EMA expression was higher at the peripheral
portions of the tumor nests where tumor cells were more closely in
contact with FAP-expressing CAFs. Meanwhile, in HCCs with
small nest/trabecular pattern, EMA expression was rather diffuse:
the tumor cells closely intermingled with CAFs expressing FAP.
This topographic expression pattern that suggests topographic
closeness between the EMA-expressing tumor cells and CAFs of
tumor stroma, which was similar to that of K19 expression in
HCCs with fibrous stroma reported in our previous study [12].
Furthermore, the frequency of EMA expression was shown to be
significantly correlated with that of FAP expression in scirrhous
HCCs (cohort 2). Taken together, we discerned that EMA and
FAP may be important in tumor-stroma cross-talk via activation of
CAFs. To our knowledge, this is the first study to verify
topographically the expression patterns of EMA in human HCC
tissues with activated CAFs.T
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CCN2 is a fibrogenic cytokine that mediates almost all fibrotic
processes [13]. Overexpression of CCN2 in fibroblasts produces
large amounts of extracellular matrix and enhances benign fibrotic
changes in the pancreas, kidney, lung, and liver [28–31]. In
addition to benign fibrotic processes, CCN2 overexpression is also
known to be responsible for pathologic fibrosis, including
desmoplastic reaction in cancer [32]. Inhibition of TGF-b, which
is typically activated in HCCs with fibrous stroma [12], was
reported to downregulate CCN2 and block tumor-stroma cross-
talk and tumor progression in HCC [14]. Two prior studies
assessing the prognostic effects of CCN2 expression in HCCs
disclosed that the expression levels of intra tumoral CCN2 were
significantly higher in HCCs with bone metastasis [33,34].
Moreover, the CCN2 mRNA was expressed in tumor cells of
EMT-phenotype in HCC, facilitating migration, invasion, and
progression of the tumor cells in vitro [35]. In accordance with
these studies, we discovered that CCN2 expression is related to
more infiltrative growth without tumor capsule and worse DFS in
HCCs. Although CCN2 is well known as fibrogenic cytokine, to
our knowledge, no study has reported on a relationship between
CCN2 expression and tumor fibrous stromal components in HCC.
Herein, we demonstrated significant CCN2 expression in HCCs
with fibrous stroma ($5% of the tumor area) (cohort 1) and even
greater expression in scirrhous HCCs (fibrous stroma$50% of the
tumor area) (cohort 2). The expression of CCN2 was correlated
with absence of capsule formation, which is a characteristic
pathological feature of invasive tumor growth, as well as frequent
K19 expression (cohort 1), larger tumor size (cohort 2), and shorter
disease free survival (cohort 1 and 2). Furthermore, expression of
CCN2 was shown to be associated with EMA expression in both
cohorts, which seems to be important in epithelial-stromal
interactions in HCC. Taken together, we suggest that CCN2
expression is involved in the activation of CAFs and tumor fibrous
stroma formation, which is related to the aggressive biological
behavior of HCC. [12]
Interestingly, CCN2 expression was well correlated with K19
expression in the HCC specimens of this study. We previously
reported that HCCs expressing stemness-related markers, such as
Figure 4. Disease-free survival (DFS) analysis of hepatocellular carcinoma (HCC) patients according to the expressions of
connective tissue growth factor (CCN2), epithelial membrane antigen (EMA), and fibroblast activation protein (FAP). A–C) DFS
analysis of HCC patients in cohort 1. HCC patients with positive expression of CCN2 (A) exhibit a significantly worse DFS curve compared to those
without (P= 0.005). There is no significant difference in DFS rate according expression of EMA (B) or FAP (C). D–F) DFS analysis of scirrhous HCC
patients (cohort 2). CCN2 (D) and EMA (E) expression significantly influences DFS rates among scirrhous HCC patients (P= 0.023 and P= 0.048,
respectively), whereas there is no significant difference in DFS rate according to FAP expression (F).
doi:10.1371/journal.pone.0105094.g004
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K19, exhibited greater formation of fibrous stroma, more vascular
invasion, and more aggressive clinical outcomes upon activation of
EMT-related genes [36]. The correlations between CCN2, K19,
and fibrous stroma are of interest, in that they might imply that
stemness is regulated by tumor stroma, as in various other tumors.
[37–39] Accordingly, the underlying molecular mechanisms
thereof should be further investigated, as delineating the micro-
Table 3. Univariate and multivariate analysis of disease-free survival rate for HCC in cohort 1.
Univariate Multivariate
HR 95% CI P HR 95% CI P
Sex
Female 1
Male 0.989 0.620–1.579 0.965
Age (years)
,55 1
$55 1.200 0.820–1.755 0.349
Etiology
Non-viral 1
Viral 0.939 0.536–1.645 0.825
Cirrhosis
Absent 1 1
Present 1.859 1.251–2.761 0.002 1.815 1.208–2.729 0.004
Tumor size (cm)
,5 1 1
$5 1.977 1.309–2.986 0.001 1.533 0.952–2.468 0.079
Edmondson grade
I/II 1 1
III/IV 1.685 1.150–2.469 0.007 1.186 0.779–1.804 0.427
Vascular invasion
Absent 1 1
Present 2.179 1.437–3.302 ,0.001 1.764 1.118–2.784 0.015
Multiplicity
Single 1 1
Multiple 2.250 1.470–3.445 ,0.001 1.399 0.787–2.488 0.253
Stage (by AJCC)
I–II 1 1
III–IV 4.652 2.636–8.211 ,0.001 2.214 0.921–4.898 0.077
Fibrous stroma
Not abundant 1
Abundant 0.931 0.548–1.581 0.790
K19 expression
Negative 1
Positive 0.952 0.609–1.487 0.828
CCN2 expression
Negative 1 1
Positive 1.886 1.207–2.948 0.005 1.561 0.989–2.465 0.056
EMA expression
Negative 1
Positive 0.782 0.460–1.329 0.363
FAP expression
Negative 1
Positive 0.617 0.252–1.515 0.292
HCC, Hepatocellular carcinoma; CCN2, Connective tissue growth factor; EMA, Epithelial membrane antigen; FAP, Fibroblast activation protein.
doi:10.1371/journal.pone.0105094.t003
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environmental regulation of stemness might provide new targets
for cancer therapy. [40]
In conclusion, the expressions of CCN2, EMA, and FAP may
be involved in the formation of tumor fibrous stroma, along with
activation of CAFs in HCC, giving rise to aggressive behavior.
Significant correlation between EMA-expressing tumor cells and
FAP-expressing CAFs and their topographic closeness suggest
possible cross-talk between epithelial cells and stromal cells in the
tumor microenvironment of HCC.
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